Skip to main content
Senti Biosciences, Inc. logo

Senti Biosciences, Inc. — Investor Relations & Filings

Ticker · SNTI ISIN · US81726A1007 US Professional, scientific and technical activities
Open in API
Filings indexed 318 across all filing types
Latest filing 2026-05-26 Capital/Financing Update
Country US United States of America
Listing US SNTI

About Senti Biosciences, Inc.

https://www.sentibio.com/

Senti Biosciences, Inc. is a clinical-stage biotechnology company developing a new generation of cell and gene therapies. The company's core technology is its synthetic biology platform, which designs and optimizes proprietary "Gene Circuits." These circuits, created from novel combinations of DNA sequences, are engineered to reprogram cells with biological logic, enabling them to sense inputs, compute decisions, and respond to their cellular environments. This approach aims to create smarter medicines with enhanced therapeutic effectiveness and safety. Senti Bio is applying its Gene Circuit technology to develop a pipeline of product candidates, primarily for the treatment of cancer, designed to precisely target and eliminate malignant cells while sparing healthy tissue.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 92% confidence The document is a United States SEC Form 8-K current report disclosing the entry into material definitive agreements and issuance of $10 million Senior Secured Convertible Notes, as well as the creation of a direct financial obligation under those notes. This constitutes a company financing activity (capital structure change). Accordingly, it best fits the Capital/Financing Update category.
2026-05-26 English
10-Q
Interim / Quarterly Report
2026-05-14 English
8-K
Earnings Release Classification · 85% confidence The document is a Form 8-K “Current Report” disclosing Item 2.02 “Results of Operations and Financial Condition” and furnishing a press release announcing the company’s quarterly financial results for the period ended March 31, 2026. This aligns with the definition of an Earnings Release (ER)—the initial announcement of quarterly/periodical financial results. Hence, the appropriate classification is ER. Q1 2026
2026-05-14 English
S-8 - Senti Biosciences, Inc. (0001854270) (Filer)
Share Issue/Capital Change Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used for registering securities under employee benefit plans such as stock incentive plans and employee stock purchase plans. It includes detailed legal and indemnification provisions related to directors and officers. The document references incorporation by reference of the Annual Report on Form 10-K and other filings but is itself a registration statement for securities, not a financial report or earnings release. Form S-8 filings are related to share issuance under employee plans and thus fall under the category of Share Issue/Capital Change announcements.
2026-04-24 English
S-8 POS - Senti Biosciences, Inc. (0001854270) (Filer)
Transaction in Own Shares Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to multiple Form S-8 Registration Statements filed with the SEC. Form S-8 is used for registering securities to be offered under employee benefit plans such as stock incentive plans and employee stock purchase plans. The document discusses deregistration of unsold securities under these plans following a corporate reorganization. It is a regulatory filing related to securities registration and deregistration, not a financial report, earnings release, or capital update. The document is not a report itself but an amendment to registration statements, fitting the category of a Transaction in Own Shares (POS) because it deals with deregistration of securities related to equity incentive plans and employee stock purchase plans. The document length is over 7000 characters, so it is not a mere announcement but a substantive filing. Therefore, the best classification is POS (Transaction in Own Shares).
2026-04-24 English
S-8 POS - Senti Biosciences, Inc. (0001854270) (Filer)
Transaction in Own Shares Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to multiple Form S-8 registration statements filed with the SEC. It relates to deregistration of securities that remain unissued or unsold under various equity incentive plans. The document includes details about a corporate reorganization and the conversion of shares as part of a merger. Form S-8 is used for registering securities to be offered under employee benefit plans. The document is a regulatory filing concerning securities registration and deregistration, not a financial report, earnings release, or presentation. It is not a report publication announcement since it contains substantive information about the deregistration and reorganization. Therefore, the appropriate classification is Transaction in Own Shares (POS), which covers share repurchase/issuance and related filings including deregistration of securities under employee plans.
2026-04-24 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.